ReviewFrontiers in microbiology2025
The microbial landscape of tumors: a deep dive into intratumoral microbiota.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pathology-derived clinical micro-architectural diagnostics of tumour-microbiome interactions in colorectal cancer.Journal of translational medicine · 2026Article
- What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs.International journal of molecular sciences · 2026Review
- Soluble factors from Aspergillus fumigatus promote NF-κB/AKT/ERK activation and pro-tumor phenotypes in lung cancer cells in vitro.Archives of microbiology · 2026Article
- Neoplastic Disorders and Cardiovascular Comorbidities in Geriatric Patients: A Simple Association?Geriatrics (Basel, Switzerland) · 2026Review
- Integrated multi-omic analysis unravels the characteristics of the metabolism-related intratumoral microbes and establishes a novel signature for predicting prognosis and therapeutic response in lung adenocarcinoma.Translational cancer research · 2025Article
- Microbial signatures in metastatic cancer.Frontiers in medicine · 2025Review
- Lung cancer immunotherapy in 2025: where we stand and what comes next?Frontiers in immunology · 2025Review
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms in the human body play crucial roles in various health and disease processes. Research indicates that diverse bacterial species are implicated in numerous cancer types. Apart from its involvement in cancer initiation and progression, the microbiome holds promise as a biomarker for diagnosing cancer, assessing risk, and determining prognosis. Intratumoral microbes profoundly impact tumor biology by regulating the initiation and progression of tumors and modulating their response to chemotherapy, radiotherapy, and immunotherapy. A deeper understanding of the role of the intratumoral microbiome in cancer requires further investigation into its effects and underlying mechanisms. This review delves into the significance of intratumoral bacteria in cancer initiation, progression, and metastasis, their impact on cancer treatment outcomes, and Approaches Employed for Profiling the Intratumoral Microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.